Developer docs
API playgroundTry for free, no card

Search company profiles

Aprecia Pharmaceuticals

Full company profile

uuid0000swz

Namestring
Aprecia Pharmaceuticals
Legal namestring
Aprecia Pharmaceuticals, LLC
Websiteurl
aprecia.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

Aprecia Pharmaceuticals, LLC is a privately held specialty pharmaceutical company headquartered in Mason, Ohio, that commercializes binder jetting three-dimensional printing (3DP) for pharmaceutical manufacturing. Founded in 2003, the company operates under an exclusive worldwide license from MIT for pharmaceutical applications of 3DP technology, with the core approach tracing to doctoral research at MIT by current CTO Jaedeok Yoo. Aprecia's technology stack comprises three proprietary platforms: the ZipDose formulation platform (rapidly disintegrating oral dosage forms carrying up to 1,000 mg active ingredient per dose without compression), the Open Bed 3DP-Tablet Forming Platform (racetrack-based commercial-scale production without molds/dies), and the Z-Form Flex In Blister system (layer-by-layer printing directly into primary packaging with integrated Process Analytical Technology, in-line inspection, and full traceability). The company holds 126 granted patents and 52 pending patents covering the underlying machinery and pharmaceutical applications.

The company monetizes across three streams: licensing the 3DP technology platforms to pharmaceutical partners; providing specialty contract development and manufacturing organization (CDMO) services spanning pre-formulation, clinical trial supply, and commercial-scale cGMP production; and selling its proprietary FDA-approved product SPRITAM (levetiracetam)—the world's first 3D-printed prescription drug—through licensed distribution partner Prasco Laboratories, a related entity under controlling parent Scion Companies. SPRITAM is approved as adjunctive therapy for partial onset, myoclonic, and generalized tonic-clonic seizures, with a July 2025 label extension to nasogastric and gastrostomy tube administration.

Aprecia serves three customer segments: pharmaceutical and biotech companies seeking differentiated drug delivery formats and advanced manufacturing; patients with dysphagia and high-dose requirements (epilepsy, pediatric, geriatric, and tube-fed populations); and government/defense customers (U.S. HHS/ASPR and DARPA via the Battelle partnership for agile point-of-need manufacturing). The company maintains U.S. operations across Mason (HQ), Blue Ash (190,000 sq ft manufacturing), and a historical East Windsor, NJ facility, with international reach through partnerships with CMIC (Japan), Glatt (Europe), Nanoform (Finland), and Merck KGaA (functional excipients). Complementary strategic partnerships include Ohio State University, Purdue University/US Pharmacopeia, Apprentice.io (AI-powered MES), and STAQ Pharma.

Short descriptiontext

Aprecia Pharmaceuticals (Mason, OH) commercializes proprietary binder jetting 3D printing technology for pharmaceutical manufacturing under an exclusive MIT license. The company offers technology licensing, specialty CDMO development and manufacturing services, and SPRITAM (levetiracetam), the first FDA-approved 3D-printed drug.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMason, United States
HQ citystring
Mason
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
3D printed pharmaceuticals, pharmaceutical CDMO services, orodispersible tablet technology, novel drug formulation, contract pharmaceutical manufacturing
Industry4 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical 3D Printing / Specialty CDMO
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing
TypeLicensing Royalties
Description

Aprecia licenses its exclusive 3DP technology platform to pharmaceutical partners as a means to extend product lines, improve patient reach and experience, and address FDA requirements as a pediatric delivery form.

aprecia.com
2Contract Development and Manufacturing (CDMO Services)
TypeProfessional Services
Description

Aprecia operates as a specialty CDMO offering development services (novel formulations, 3DP manufacturing, reducing risk, and accelerating product development) and manufacturing services (from clinical trial supply to commercial-scale production) to pharmaceutical clients globally.

aprecia.com
3Proprietary Product Sales (SPRITAM)
TypeOne Time License
Description

Aprecia's proprietary FDA-approved product SPRITAM (levetiracetam) is distributed by Prasco Laboratories. Revenue is generated through product sales via this licensing arrangement.

aprecia.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Development Services and Manufacturing Services are offered to pharmaceutical partners on a project-by-project basis.
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed

aprecia.com
2SPRITAM (levetiracetam) - available as prescription pharmaceutical product distributed via Prasco Laboratories.
ModelOtherBilling cadencePay-as-you-go
Notes

Available through standard pharmaceutical retail channels; specific pricing not disclosed in source material

aprecia.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1SPRITAM
Description

The world's first and only FDA-approved 3D printed pharmaceutical product. SPRITAM (levetiracetam) is an oral suspension tablet for epilepsy treatment that rapidly disintegrates with a sip of liquid. Licensed to Prasco Laboratories.

aprecia.com
+6 more records
Core offering1 text field

Aprecia Pharmaceuticals develops and manufactures pharmaceutical products using proprietary binder jet 3D printing (3DP) technology. The company operates as a specialty CDMO offering formulation development, cGMP manufacturing, and technology licensing to pharmaceutical partners, and commercializes the FDA-approved product SPRITAM (levetiracetam) — the world's first 3D-printed prescription drug. Core platforms include ZipDose Technology, Open Bed 3DP-Tablet Forming, and the Z-Form Flex In Blister 3DP-Tablet Production System.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Aprecia Pharmaceuticals is a specialty pharmaceutical company offering a platform-plus-modules architecture centered on its proprietary ZipDose 3D printing technology. The core technology includes the Open Bed 3DP-Tablet Forming Platform for commercial-scale production and the Z-Form Flex In Blister system for primary packaging integration. The company's flagship commercial product is SPRITAM (levetiracetam), the world's first and only FDA-approved 3D printed pharmaceutical. Services include drug development, manufacturing, and CMC support. Aprecia holds 126 granted patents and 52 pending in 3DP pharmaceutical applications.

Product and service7 records
1SPRITAM (levetiracetam)
CategoryProprietary pharmaceutical product
Description

The world's first and only FDA-approved 3D-printed pharmaceutical product. SPRITAM is a porous oral dosage form that rapidly disintegrates with a sip of liquid, enabling delivery of up to 1,000 mg of levetiracetam. Indicated as adjunctive therapy for epilepsy (partial onset, myoclonic, and primary generalized tonic-clonic seizures) in patients with swallowing difficulties; also approved for nasogastric (NG) and gastrostomy (G) tube administration. Distributed via Prasco Laboratories.

2ZipDose Technology Platform
CategoryTechnology platform / IP
Description

Proprietary 3D printing-based formulation platform that enables medicine to swiftly disperse in the patient's mouth with a sip of water or other liquid. Achieves dosage strengths commercially unattainable with current fast-melt technologies and supports engineered and coated particles (taste masking, modified release) on large-dose products because no compression is used during manufacturing.

3Open Bed 3DP-Tablet Forming Platform
CategoryManufacturing platform / CDMO technology
Description

Production platform enabling 3DP-tablet printing without molds or dyes. Features a cam-driven oval racetrack with linked moving build trays, continuous powder feeding and spreading, stationary high-resolution printheads, unprinted powder capture and recirculation, and a humidity-controlled drying oven. Capable of producing orodispersible dosage forms in excess of 1,000 mg of active ingredients, with bed-to-bed powder transfer for rapid prototyping in early formulation.

4Z-Form Flex (In Blister 3DP-Tablet Production System)
CategoryManufacturing platform / CDMO technology
Description

In-blister 3DP-tablet production system that prints tablets directly into primary packaging (in-cavity). Provides layer-by-layer precision control, ability to combine multiple APIs, integrated Process Analytical Technology (PAT), in-line inspection, surface logo printing, traceability at card and cavity level, and high-potent capabilities. Enables real-time release and full product traceability from bulk powder to packaged finished doses.

5Development Services
CategoryCDMO service
Description

Collaborative CDMO development services covering novel formulations, 3DP manufacturing feasibility, risk reduction, and accelerated product development. Includes pre-formulation studies, formulation development, analytical development, process development, and scale-up across orodispersible, sublingual/buccal, and traditional tablet formats.

6Manufacturing Services
CategoryCDMO service
Description

cGMP-compliant pharmaceutical manufacturing services from clinical trial supply (Phase I–III) through commercial-scale production. Performed in an FDA-inspected and registered facility. Leverages Aprecia's 3DP platforms with integrated PAT and real-time release capability.

7CMC Support
CategoryCDMO service
Description

Comprehensive Chemistry, Manufacturing, and Controls support including raw materials selection, analytical methods development, stability testing, physicochemical properties analysis, manufacturing best practices, and quality control for partners developing 3DP-enabled drug products.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-16
Description

Aprecia partnered with Apprentice.io to implement its AI-powered manufacturing platform at Aprecia's Ohio facility. The cloud-native platform delivers digital manufacturing capabilities and no-code integration tools to accelerate production workflows, ensure consistent execution at scale, and enable rapid deployment across multiple production sites.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-19
Description

Battelle and Aprecia were awarded a DARPA agreement (through HHS/ASPR IBMSC funding) for the EQUIP-A-Pharma research program. Battelle is building a custom small-scale chemical synthesis platform while Aprecia provides its Z-Form Flex 3DP technology. The program aims to create agile pharmaceutical manufacturing sites producing both active pharmaceutical ingredients and finished dosage forms at the same location.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2021-08-04
Description

Purdue University, in partnership with US Pharmacopeia and sponsorship from Aprecia, launched a pharmaceutical 3D printing educational forum. Aprecia sponsors the series as the global leader in 3DP pharmaceutical manufacturing. The forum brings together global 3DP experts to discuss technological advancements in process, equipment, systems, product applications, and manufacturing capabilities.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2021-04-21
Description

Collaboration to explore synergies between Nanoform's nanoparticle technologies and Aprecia's ZipDose 3DP platform for nanoparticle-enabled 3DP dosage forms. Initial target: combining Nanoform's fast dissolution nanoformed particles with ZipDose for rapid disintegration to enable high-performance buccal and oral delivery. Benefits may include lower dosage products, less excipient content, and reduced pill burden.

5Glatt Pharmaceutical Services
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2021-02-23
Description

Glatt Pharmaceutical Services and Aprecia partnered to accelerate and expand the use of Glatt's multiparticulate technologies through Aprecia's 3DP manufacturing. The collaboration targets existing products for modified release 505(b)(2) brand line extensions and new chemical entities through accelerated clinical development and patient-focused dosage forms.

aprecia.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-12-21
Description

Aprecia established a long-term partnership with Battelle to accelerate and expand pharmaceutical 3DP capabilities. Battelle provides development engineering support for equipment design and prototyping.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-03-07
Description

Aprecia and CMIC, a leading CDMO in Japan, established an agreement to bring 3DP pharmaceutical products to Japan. CMIC provides business development and commercialization support in Japan.

8Ohio State University
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Fostering educational leadership, talent development, and R&D support to drive innovation in pharmaceutical 3DP.

aprecia.com
Strategic tierSecondaryTypeTechnology or Integration
Description

Merck provides access to functional excipients for use with Aprecia's 3DP technology platforms. A scientific poster was published demonstrating binder jetting technology for tablet manufacturing of loaded Parteck SLC (a mesoporous silica product from Merck KGaA) for solubility enhancement.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

STAQ Pharma provides critical medications for pediatric and adult patients across the United States. Nature of collaboration with Aprecia relates to ensuring reliable supply of essential medications.

Strategic tierCoreTypeTechnology or Integration
Description

Aprecia holds an exclusive, worldwide license from MIT for pharmaceutical applications of the 3DP technology. MIT's technology underlies Aprecia's ZipDose and 3DP manufacturing platforms.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Prasco Laboratories, under Scion Companies (the controlling parent), holds a controlling interest in Aprecia and serves as the licensed distribution partner for SPRITAM (levetiracetam). SPRITAM is distributed by Prasco Laboratories.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Leading Japanese CDMO and Aprecia's exclusive distribution/CDMO partner for 3DP pharmaceutical products in Japan. Direct regional channel partner and a comparable CDMO-type competitor inside the Japanese market.

TypeBroad incumbent
Description

Specialty CDMO focused on small-molecule active pharmaceutical ingredients and finished dosage forms. Comparable in size and CDMO-style service offering, competing for similar pharma development and manufacturing programs.

TypeBroad incumbent
Description

US-headquartered specialty CDMO providing drug product development, manufacturing, and analytical services from clinical to commercial scale. Similar specialty-CDMO positioning to Aprecia's services business, but without a 3DP-native platform.

TypeBroad incumbent
Description

Operates one of the largest global pharmaceutical CDMO networks via its Patheon business. Overlaps with Aprecia in clinical-through-commercial drug product services and has the scale to add 3D printing capabilities.

TypeOthers
Description

Provider of an AI-powered, cloud-native manufacturing execution platform that Aprecia is deploying at its Ohio facility. Comparable as a manufacturing-software partner in Aprecia's 'Pharma 4.0' stack rather than as a direct CDMO competitor.

TypeBroad incumbent
Description

One of the world's largest pharmaceutical CDMOs across oral, injectable, and biologic dosage forms. Competes with Aprecia in pharma development and manufacturing services from clinical through commercial scale, but with a vastly broader portfolio.

7Merck KGaA (Life Science / MilliporeSigma)
TypeOthers
Description

Supplies functional excipients (e.g., Parteck SLC) used with Aprecia's 3DP binder jetting platforms. Indirectly comparable as a critical input supplier and strategic ecosystem partner for pharmaceutical 3DP applications.

TypeDirect peer
Description

UK-based pharmaceutical 3D printing company developing personalized medicines and printed dosage forms, including orodispersible tablets. Closest European direct competitor in pharma-grade 3DP.

TypeBroad incumbent
Description

Global CDMO with deep capabilities in small molecules, biologics, and cell & gene therapies. A broad incumbent competing for outsourced pharma development and manufacturing budgets that Aprecia also targets through its CDMO services.

TypeDirect peer
Description

Chinese-founded 3D-printed pharmaceutical company also cited as a leading global player alongside Aprecia in the 3D printed drugs market. Most direct head-to-head on binder-jetting oral dosage form technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aprecia Pharmaceuticals

Pharmaceutical 3D Printing / Specialty CDMOaprecia.com

Aprecia Pharmaceuticals (Mason, OH) commercializes proprietary binder jetting 3D printing technology for pharmaceutical manufacturing under an exclusive MIT license. The company offers technology licensing, specialty CDMO development and manufacturing services, and SPRITAM (levetiracetam), the first FDA-approved 3D-printed drug.

What Aprecia Pharmaceuticals does

Aprecia Pharmaceuticals, LLC is a privately held specialty pharmaceutical company headquartered in Mason, Ohio, that commercializes binder jetting three-dimensional printing (3DP) for pharmaceutical manufacturing. Founded in 2003, the company operates under an exclusive worldwide license from MIT for pharmaceutical applications of 3DP technology, with the core approach tracing to doctoral research at MIT by current CTO Jaedeok Yoo. Aprecia's technology stack comprises three proprietary platforms: the ZipDose formulation platform (rapidly disintegrating oral dosage forms carrying up to 1,000 mg active ingredient per dose without compression), the Open Bed 3DP-Tablet Forming Platform (racetrack-based commercial-scale production without molds/dies), and the Z-Form Flex In Blister system (layer-by-layer printing directly into primary packaging with integrated Process Analytical Technology, in-line inspection, and full traceability). The company holds 126 granted patents and 52 pending patents covering the underlying machinery and pharmaceutical applications.

The company monetizes across three streams: licensing the 3DP technology platforms to pharmaceutical partners; providing specialty contract development and manufacturing organization (CDMO) services spanning pre-formulation, clinical trial supply, and commercial-scale cGMP production; and selling its proprietary FDA-approved product SPRITAM (levetiracetam)—the world's first 3D-printed prescription drug—through licensed distribution partner Prasco Laboratories, a related entity under controlling parent Scion Companies. SPRITAM is approved as adjunctive therapy for partial onset, myoclonic, and generalized tonic-clonic seizures, with a July 2025 label extension to nasogastric and gastrostomy tube administration.

Aprecia serves three customer segments: pharmaceutical and biotech companies seeking differentiated drug delivery formats and advanced manufacturing; patients with dysphagia and high-dose requirements (epilepsy, pediatric, geriatric, and tube-fed populations); and government/defense customers (U.S. HHS/ASPR and DARPA via the Battelle partnership for agile point-of-need manufacturing). The company maintains U.S. operations across Mason (HQ), Blue Ash (190,000 sq ft manufacturing), and a historical East Windsor, NJ facility, with international reach through partnerships with CMIC (Japan), Glatt (Europe), Nanoform (Finland), and Merck KGaA (functional excipients). Complementary strategic partnerships include Ohio State University, Purdue University/US Pharmacopeia, Apprentice.io (AI-powered MES), and STAQ Pharma.

Aprecia Pharmaceuticals firmographics

Firmographics
Name
Aprecia Pharmaceuticals
Legal name
Aprecia Pharmaceuticals, LLC
Website
https://aprecia.com
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
51–100 employees
Short description
Aprecia Pharmaceuticals (Mason, OH) commercializes proprietary binder jetting 3D printing technology for pharmaceutical manufacturing under an exclusive MIT license. The company offers technology licensing, specialty CDMO development and manufacturing services, and SPRITAM (levetiracetam), the first FDA-approved 3D-printed drug.
Ownership category
akta.pro rank

Aprecia Pharmaceuticals industry classification

Industry
Product category
Pharmaceutical 3D Printing / Specialty CDMO
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • 3D printed pharmaceuticals
  • Pharmaceutical CDMO services
  • Orodispersible tablet technology
  • Novel drug formulation
  • Contract pharmaceutical manufacturing

Where Aprecia Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Mason
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Aprecia Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Technology Licensing: Aprecia licenses its exclusive 3DP technology platform to pharmaceutical partners as a means to extend product lines, improve patient reach and experience, and address FDA requirements as a pediatric delivery form.
  2. Contract Development and Manufacturing (CDMO Services): Aprecia operates as a specialty CDMO offering development services (novel formulations, 3DP manufacturing, reducing risk, and accelerating product development) and manufacturing services (from clinical trial supply to commercial-scale production) to pharmaceutical clients globally.
  3. Proprietary Product Sales (SPRITAM): Aprecia's proprietary FDA-approved product SPRITAM (levetiracetam) is distributed by Prasco Laboratories. Revenue is generated through product sales via this licensing arrangement.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractDevelopment Services and Manufacturing Services are offered to pharmaceutical partners on a project-by-project basis.
OtherPay-as-you-goSPRITAM (levetiracetam) - available as prescription pharmaceutical product distributed via Prasco Laboratories.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Aprecia Pharmaceuticals product offering

Product offering

Core offering

Aprecia Pharmaceuticals develops and manufactures pharmaceutical products using proprietary binder jet 3D printing (3DP) technology. The company operates as a specialty CDMO offering formulation development, cGMP manufacturing, and technology licensing to pharmaceutical partners, and commercializes the FDA-approved product SPRITAM (levetiracetam) — the world's first 3D-printed prescription drug. Core platforms include ZipDose Technology, Open Bed 3DP-Tablet Forming, and the Z-Form Flex In Blister 3DP-Tablet Production System.

Product overview

Aprecia Pharmaceuticals is a specialty pharmaceutical company offering a platform-plus-modules architecture centered on its proprietary ZipDose 3D printing technology. The core technology includes the Open Bed 3DP-Tablet Forming Platform for commercial-scale production and the Z-Form Flex In Blister system for primary packaging integration. The company's flagship commercial product is SPRITAM (levetiracetam), the world's first and only FDA-approved 3D printed pharmaceutical. Services include drug development, manufacturing, and CMC support. Aprecia holds 126 granted patents and 52 pending in 3DP pharmaceutical applications.

Differentiator

Problem solved

Functional benefit

Brands

  • SPRITAM: The world's first and only FDA-approved 3D printed pharmaceutical product. SPRITAM (levetiracetam) is an oral suspension tablet for epilepsy treatment that rapidly disintegrates with a sip of liquid. Licensed to Prasco Laboratories.
  • ZipDose
  • ZipDose Technology
  • ZipDose Technology Platform
  • Z-Form Flex
  • Open Bed 3DP-Tablet Forming Platform
  • In Blister 3DP-Tablet Production System

Products and services

  • SPRITAM (levetiracetam) The world's first and only FDA-approved 3D-printed pharmaceutical product. SPRITAM is a porous oral dosage form that rapidly disintegrates with a sip of liquid, enabling delivery of up to 1,000 mg of levetiracetam. Indicated as adjunctive therapy for epilepsy (partial onset, myoclonic, and primary generalized tonic-clonic seizures) in patients with swallowing difficulties; also approved for nasogastric (NG) and gastrostomy (G) tube administration. Distributed via Prasco Laboratories.
  • ZipDose Technology Platform Proprietary 3D printing-based formulation platform that enables medicine to swiftly disperse in the patient's mouth with a sip of water or other liquid. Achieves dosage strengths commercially unattainable with current fast-melt technologies and supports engineered and coated particles (taste masking, modified release) on large-dose products because no compression is used during manufacturing.
  • Open Bed 3DP-Tablet Forming Platform Production platform enabling 3DP-tablet printing without molds or dyes. Features a cam-driven oval racetrack with linked moving build trays, continuous powder feeding and spreading, stationary high-resolution printheads, unprinted powder capture and recirculation, and a humidity-controlled drying oven. Capable of producing orodispersible dosage forms in excess of 1,000 mg of active ingredients, with bed-to-bed powder transfer for rapid prototyping in early formulation.
  • Z-Form Flex (In Blister 3DP-Tablet Production System) In-blister 3DP-tablet production system that prints tablets directly into primary packaging (in-cavity). Provides layer-by-layer precision control, ability to combine multiple APIs, integrated Process Analytical Technology (PAT), in-line inspection, surface logo printing, traceability at card and cavity level, and high-potent capabilities. Enables real-time release and full product traceability from bulk powder to packaged finished doses.
  • Development Services Collaborative CDMO development services covering novel formulations, 3DP manufacturing feasibility, risk reduction, and accelerated product development. Includes pre-formulation studies, formulation development, analytical development, process development, and scale-up across orodispersible, sublingual/buccal, and traditional tablet formats.
  • Manufacturing Services cGMP-compliant pharmaceutical manufacturing services from clinical trial supply (Phase I–III) through commercial-scale production. Performed in an FDA-inspected and registered facility. Leverages Aprecia's 3DP platforms with integrated PAT and real-time release capability.
  • CMC Support Comprehensive Chemistry, Manufacturing, and Controls support including raw materials selection, analytical methods development, stability testing, physicochemical properties analysis, manufacturing best practices, and quality control for partners developing 3DP-enabled drug products.

Companies that use Aprecia Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Aprecia Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Aprecia Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, secondary and minor.

  • Apprentice.iocoreTechnology or Integration · 16 September 2025Aprecia partnered with Apprentice.io to implement its AI-powered manufacturing platform at Aprecia's Ohio facility. The cloud-native platform delivers digital manufacturing capabilities and no-code integration tools to accelerate production workflows, ensure consistent execution at scale, and enable rapid deployment across multiple production sites.
  • BattellecoreStrategic or Co-development Partner · 19 August 2025Battelle and Aprecia were awarded a DARPA agreement (through HHS/ASPR IBMSC funding) for the EQUIP-A-Pharma research program. Battelle is building a custom small-scale chemical synthesis platform while Aprecia provides its Z-Form Flex 3DP technology. The program aims to create agile pharmaceutical manufacturing sites producing both active pharmaceutical ingredients and finished dosage forms at the same location.
  • Purdue UniversitysecondaryStrategic or Co-development Partner · 4 August 2021Purdue University, in partnership with US Pharmacopeia and sponsorship from Aprecia, launched a pharmaceutical 3D printing educational forum. Aprecia sponsors the series as the global leader in 3DP pharmaceutical manufacturing. The forum brings together global 3DP experts to discuss technological advancements in process, equipment, systems, product applications, and manufacturing capabilities.
  • NanoformsecondaryStrategic or Co-development Partner · 21 April 2021Collaboration to explore synergies between Nanoform's nanoparticle technologies and Aprecia's ZipDose 3DP platform for nanoparticle-enabled 3DP dosage forms. Initial target: combining Nanoform's fast dissolution nanoformed particles with ZipDose for rapid disintegration to enable high-performance buccal and oral delivery. Benefits may include lower dosage products, less excipient content, and reduced pill burden.
  • Glatt Pharmaceutical ServicessecondaryStrategic or Co-development Partner · 23 February 2021Glatt Pharmaceutical Services and Aprecia partnered to accelerate and expand the use of Glatt's multiparticulate technologies through Aprecia's 3DP manufacturing. The collaboration targets existing products for modified release 505(b)(2) brand line extensions and new chemical entities through accelerated clinical development and patient-focused dosage forms.
  • Battelle (Long-Term Partnership)coreStrategic or Co-development Partner · 21 December 2020Aprecia established a long-term partnership with Battelle to accelerate and expand pharmaceutical 3DP capabilities. Battelle provides development engineering support for equipment design and prototyping.
  • CMICsecondaryChannel Partner/ Reseller/ Distributor · 7 March 2019Aprecia and CMIC, a leading CDMO in Japan, established an agreement to bring 3DP pharmaceutical products to Japan. CMIC provides business development and commercialization support in Japan.
  • Ohio State UniversityminorStrategic or Co-development PartnerFostering educational leadership, talent development, and R&D support to drive innovation in pharmaceutical 3DP.
  • Merck (Merck KGaA)secondaryTechnology or IntegrationMerck provides access to functional excipients for use with Aprecia's 3DP technology platforms. A scientific poster was published demonstrating binder jetting technology for tablet manufacturing of loaded Parteck SLC (a mesoporous silica product from Merck KGaA) for solubility enhancement.
  • STAQ PharmaminorChannel Partner/ Reseller/ DistributorSTAQ Pharma provides critical medications for pediatric and adult patients across the United States. Nature of collaboration with Aprecia relates to ensuring reliable supply of essential medications.
  • Massachusetts Institute of Technology (MIT)coreTechnology or IntegrationAprecia holds an exclusive, worldwide license from MIT for pharmaceutical applications of the 3DP technology. MIT's technology underlies Aprecia's ZipDose and 3DP manufacturing platforms.
  • Prasco Laboratories / Scion CompaniescoreChannel Partner/ Reseller/ DistributorPrasco Laboratories, under Scion Companies (the controlling parent), holds a controlling interest in Aprecia and serves as the licensed distribution partner for SPRITAM (levetiracetam). SPRITAM is distributed by Prasco Laboratories.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Aprecia Pharmaceuticals competitors and assessment

Company assessment

Regional players

  • CMIC Holdings: Leading Japanese CDMO and Aprecia's exclusive distribution/CDMO partner for 3DP pharmaceutical products in Japan. Direct regional channel partner and a comparable CDMO-type competitor inside the Japanese market.

Broad incumbents

  • Cambrex (Permira portfolio): Specialty CDMO focused on small-molecule active pharmaceutical ingredients and finished dosage forms. Comparable in size and CDMO-style service offering, competing for similar pharma development and manufacturing programs.
  • Alcami: US-headquartered specialty CDMO providing drug product development, manufacturing, and analytical services from clinical to commercial scale. Similar specialty-CDMO positioning to Aprecia's services business, but without a 3DP-native platform.
  • Thermo Fisher Scientific (Patheon CDMO): Operates one of the largest global pharmaceutical CDMO networks via its Patheon business. Overlaps with Aprecia in clinical-through-commercial drug product services and has the scale to add 3D printing capabilities.
  • Catalent: One of the world's largest pharmaceutical CDMOs across oral, injectable, and biologic dosage forms. Competes with Aprecia in pharma development and manufacturing services from clinical through commercial scale, but with a vastly broader portfolio.
  • Lonza: Global CDMO with deep capabilities in small molecules, biologics, and cell & gene therapies. A broad incumbent competing for outsourced pharma development and manufacturing budgets that Aprecia also targets through its CDMO services.

Others

  • Apprentice.io: Provider of an AI-powered, cloud-native manufacturing execution platform that Aprecia is deploying at its Ohio facility. Comparable as a manufacturing-software partner in Aprecia's 'Pharma 4.0' stack rather than as a direct CDMO competitor.
  • Merck KGaA (Life Science / MilliporeSigma): Supplies functional excipients (e.g., Parteck SLC) used with Aprecia's 3DP binder jetting platforms. Indirectly comparable as a critical input supplier and strategic ecosystem partner for pharmaceutical 3DP applications.

Direct peers

  • FabRx Ltd: UK-based pharmaceutical 3D printing company developing personalized medicines and printed dosage forms, including orodispersible tablets. Closest European direct competitor in pharma-grade 3DP.
  • TRIASTEK: Chinese-founded 3D-printed pharmaceutical company also cited as a leading global player alongside Aprecia in the 3D printed drugs market. Most direct head-to-head on binder-jetting oral dosage form technology.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Aprecia Pharmaceuticals social profiles

Digital presence

Aprecia Pharmaceuticals compliance and trust

Trust signal

Compliance2 records

Aprecia Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aprecia Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Aprecia Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aprecia Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aprecia Pharmaceuticals

What does Aprecia Pharmaceuticals do?

Aprecia Pharmaceuticals develops and manufactures pharmaceutical products using proprietary binder jet 3D printing (3DP) technology. The company operates as a specialty CDMO offering formulation development, cGMP manufacturing, and technology licensing to pharmaceutical partners, and commercializes the FDA-approved product SPRITAM (levetiracetam) — the world's first 3D-printed prescription drug. Core platforms include ZipDose Technology, Open Bed 3DP-Tablet Forming, and the Z-Form Flex In Blister 3DP-Tablet Production System.

Is Aprecia Pharmaceuticals a public or private company?

Aprecia Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.

When was Aprecia Pharmaceuticals founded?

Aprecia Pharmaceuticals was founded in 2003. It employs 51 to 100 people.

Where is Aprecia Pharmaceuticals based?

Aprecia Pharmaceuticals is headquartered in Mason, United States, in the North America region.

How does Aprecia Pharmaceuticals make money?

Three revenue lines are on record. Technology Licensing is the primary driver. The others are contract Development and Manufacturing (CDMO Services) and proprietary Product Sales (SPRITAM).

Who are Aprecia Pharmaceuticals's main competitors?

CMIC Holdings is listed as a regional player. Broad incumbents are Cambrex (Permira portfolio), Alcami, Thermo Fisher Scientific (Patheon CDMO), Catalent and Lonza. Others are Apprentice.io and Merck KGaA (Life Science / MilliporeSigma). Direct peers are FabRx Ltd and TRIASTEK.

Does Aprecia Pharmaceuticals have an API?

No public API is recorded for Aprecia Pharmaceuticals.

What industry is Aprecia Pharmaceuticals in?

Aprecia Pharmaceuticals's product category is Pharmaceutical 3D Printing / Specialty CDMO. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TCT MagazineAprecia Pharmaceuticals: 'AM is an important expansion of the pharmaceutical manufacturing toolbox'Aprecia Pharmaceuticals is 22 months into a 28-month DARPA EQUIP-A-Pharma project to onshore pharmaceutical manufacturing. The project pairs Aprecia's 3D printing with Battelle's chemical synthesis to produce API with real-time quality analysis, aiming for two FDA ANDA filings. The company expects to reduce drug shortages and strengthen supply chains.PharmExecHow 3D Printing Speeds Up Drug ProductionAprecia Pharmaceuticals uses 3D printing to produce medications in various dosages, with real-time analytics tracking 22 data points per tablet. The company is 100% US-based, which is relevant to President Trump's April 100% tariff on imported branded medications. The process enables rapid iteration and quicker decisions based on real-time quality data.ContractpharmaMore Than ManufacturingAprecia Pharmaceuticals' binder-jet 3D printing enables flexible tablet design, with its first FDA-approved 3D printed medicine validating the technology. The EMA released guidance on 3D printing for solid oral dosage forms, and the FDA emphasizes patient-focused development. The technology supports combination therapies and personalized dosing.Healthcare BrewHealthcare Industry News & TrendsThe article reports on various developments in the healthcare industry, including a name change for polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, Lilly's collaboration with Oura on a smart ring, and the FDA's approval of 3D-printed pills by Aprecia Pharmaceuticals. It also discusses drug pricing, legal issues regarding gender-affirming care, and updates on healthcare industry trends.Healthcare Brew3D printing pills is nothing new, but its future is still wide openAprecia Pharmaceuticals received FDA approval in 2015 for Spritam, the first-ever 3D-printed pill for treating seizures, marking a milestone in drug manufacturing that traditionally occurs in dedicated facilities rather than via 3D printing. In August 2025, Aprecia secured a Defense Advanced Research Projects Agency agreement backed by the Department of Health and Human Services, partnering with Battelle to use 3D printing alongside chemical synthesis to manufacture more drugs domestically and mitigate shortages during public health emergencies. While Aprecia's president positions the technology as a reshoring solution aligned with tariff and policy pressures on pharma companies to manufacture in the US, an academic expert noted the technology is better suited for flexibility and small-batch customization rather than mass production at scale.EIN PresswireOral Solid Dosage Pharmaceutical Formulation Market Forecast 2032: USD 1349.27 Billion at 7.1% CAGRThe global Oral Solid Dosage Pharmaceutical Formulation Market is projected to grow from USD 779.44 billion in 2024 to USD 1,349.27 billion by 2032 at a 7.1% CAGR, driven by oral GLP-1 therapies for obesity and diabetes, manufacturing reshoring in North America, and adoption of continuous manufacturing and AI-driven formulation development. Key strategic moves include Novo Holdings' $16.5 billion acquisition of Catalent (finalized late 2024) and Gilead Sciences' $32 billion U.S. investment through 2030, which includes a new 180,000-square-foot AI-enabled Technical Development Center in California. The industry is also seeing 3D printing technology advances, with companies like Aprecia Pharmaceuticals developing porous, rapidly disintegrating tablets for personalized dosing.Fortunebusinessinsights3D Printed Drugs Market Size, Share, Growth Report, 2034The global 3D printed drugs market was valued at USD 140.6 billion in 2025 and is projected to reach USD 496.95 billion by 2034, growing at a CAGR of 15.06% during the forecast period 2026–2034. Key market drivers include rising demand for personalized medicine, FDA approval of products such as Spritam (levetiracetam), and technological advances in 3D printing techniques including inkjet printing, selective laser sintering, and melt extrusion deposition. North America currently leads the market, while the Asia-Pacific region is expected to experience the fastest growth, with key players including Aprecia Pharmaceutical, TRIASTEK, and FabRx Ltd.MorningstarAprecia and Apprentice.io Partner to Scale Pharmaceutical 3D Printing ManufacturingAprecia and Apprentice.io announced a partnership to scale pharmaceutical 3D printing manufacturing, with Aprecia implementing Apprentice.io's AI-powered platform at its Ohio facility. The collaboration aims to accelerate production workflows and support consistent, reliable execution at scale. The technology foundation will enable rapid deployment across multiple production sites.FinancialContent Business PageAprecia and Apprentice.io Partner to Scale Pharmaceutical 3D Printing ManufacturingAprecia and Apprentice.io announced a partnership to integrate Apprentice's AI-powered manufacturing platform at Aprecia's Ohio facility. The collaboration aims to scale Aprecia's pharmaceutical 3D printing for drug delivery, enabling rapid deployment across multiple production sites.PR Newswire3D Printed Drugs Market Size to Reach US$ 522.73 Million by 2033 - Exclusive Report by DataM IntelligenceAccording to DataM Intelligence, the global 3D printed drugs market is projected to grow from US$ 281.63 million in 2024 to US$ 522.73 million by 2033, at a compound annual growth rate of 7.2%, with North America accounting for the largest regional share at 44.8% in 2024. Aprecia Pharmaceuticals' Spritam remains the flagship product in the market, holding approximately 77.9% market share by drug type and validating the clinical viability of 3D printed pharmaceuticals since its FDA approval in 2015. The neurology segment leads applications at 51% market share, driven by the growing prevalence of neurological disorders and demand for patient-specific dosing and rapidly disintegrating formulations.